News

Clinical Phase I/II Pilot Trial Will Study New Therapy for Systemic Sclerosis

Children’s Hospital Los Angeles is recruiting Refractory Systemic Sclerosis Patients between 8 to 18 years of age for a Phase I/II pilot trial of the drug Campath-1H (ClinicalTrials.gov identifier: NCT01639573) to address whether prolonged administration of the drug can result in immunoablation. Campath-1H is a trade name…

Dartmouth Researchers Identify Various Biological Pathways That are Involved in Different Subsets of Systemic Sclerosis

Evidence is unclear about why some patients with systemic sclerosis (SSc) respond to treatment while others do not. However, a research team from Dartmouth was able to identify various biological pathways that are involved in different subsets of systemic sclerosis. Results from the research were published in two articles: the…

Ghent University Hospital Researchers Find That Young Mice Microbiome Influences Later Onset of Autoimmune Disease

Findings from a recent study in mice suggest that neonatal colonization of gut microbiota influences generalized autoimmunity in adult life, which may have implications for conditions such as Systemic Lupus Erythematosus. Specifically, researchers from Ghent University Hospital in Belgium found that when there is an increase in the levels of…

Laser Speckle Contrast Imaging Technique To Be Studied For Microvascular Dysfunction in Systemic Sclerosis

Investigators at the University Hospital, Grenoble are currently recruiting participants for a new clinical trial on Raynaud’s Disease. (ClinicalTrials.gov Identifier: NCT01743612). The clinical trial titled “Laser SPEckle Contrast Imaging Interest in Detection of Cutaneous Microvascular Dysfunction in Systemic Sclerosis,” led by Jean-Luc CRACOWSKI, MD, PhDCIC,” was…

Scleroderma Drug Developer iBio Announces U.S. Patent for iBioModulator™ Thermostable Immunomodulator Protein Portfolio

iBio, Inc. recently announced the release of a U.S. patent for a new thermostable immunomodulator protein portfolio called iBioModulator™. The company’s iBioModulator™ thermostable immunomodulator protein patents, entitled “Yersinia pests Antigens, Vaccine Compositions and Related Methods,” (Serial No. 8,945,580), includes statements about plague antigens, vaccine compositions, and a technique that produces…